nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP3A4—Thiotepa—sarcoma	0.0715	0.351	CbGbCtD
Trametinib—CYP2C8—Etoposide—sarcoma	0.0478	0.235	CbGbCtD
Trametinib—CYP3A4—Mitoxantrone—sarcoma	0.0307	0.151	CbGbCtD
Trametinib—CYP3A4—Vincristine—sarcoma	0.0211	0.104	CbGbCtD
Trametinib—CYP3A4—Etoposide—sarcoma	0.0194	0.0951	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—sarcoma	0.0132	0.0649	CbGbCtD
Trametinib—MAP2K1—embryo—sarcoma	0.00523	0.0628	CbGeAlD
Trametinib—MAP2K2—myometrium—sarcoma	0.00478	0.0575	CbGeAlD
Trametinib—MAP2K1—hematopoietic system—sarcoma	0.00466	0.056	CbGeAlD
Trametinib—MAP2K1—connective tissue—sarcoma	0.00449	0.054	CbGeAlD
Trametinib—MAP2K2—seminal vesicle—sarcoma	0.00432	0.0519	CbGeAlD
Trametinib—MAP2K1—smooth muscle tissue—sarcoma	0.00411	0.0494	CbGeAlD
Trametinib—MAP2K2—hematopoietic system—sarcoma	0.00411	0.0493	CbGeAlD
Trametinib—MAP2K1—skin of body—sarcoma	0.00406	0.0487	CbGeAlD
Trametinib—MAP2K2—smooth muscle tissue—sarcoma	0.00362	0.0435	CbGeAlD
Trametinib—MAP2K2—skin of body—sarcoma	0.00357	0.0429	CbGeAlD
Trametinib—MAP2K1—lymphoid tissue—sarcoma	0.00328	0.0395	CbGeAlD
Trametinib—MAP2K2—cardiac atrium—sarcoma	0.00312	0.0375	CbGeAlD
Trametinib—MAP2K2—uterus—sarcoma	0.0031	0.0373	CbGeAlD
Trametinib—MAP2K1—bone marrow—sarcoma	0.00299	0.0359	CbGeAlD
Trametinib—MAP2K2—lymphoid tissue—sarcoma	0.00289	0.0347	CbGeAlD
Trametinib—MAP2K2—tendon—sarcoma	0.00272	0.0326	CbGeAlD
Trametinib—MAP2K2—bone marrow—sarcoma	0.00263	0.0316	CbGeAlD
Trametinib—MAP2K1—testis—sarcoma	0.00256	0.0307	CbGeAlD
Trametinib—MAP2K1—liver—sarcoma	0.00242	0.029	CbGeAlD
Trametinib—CYP2C8—mammary gland—sarcoma	0.00233	0.028	CbGeAlD
Trametinib—MAP2K2—testis—sarcoma	0.00225	0.027	CbGeAlD
Trametinib—MAP2K2—liver—sarcoma	0.00213	0.0256	CbGeAlD
Trametinib—MAP2K1—lymph node—sarcoma	0.00185	0.0223	CbGeAlD
Trametinib—MAP2K2—lymph node—sarcoma	0.00163	0.0196	CbGeAlD
Trametinib—CYP2C8—hematopoietic system—sarcoma	0.00142	0.0171	CbGeAlD
Trametinib—CYP3A4—hematopoietic system—sarcoma	0.000963	0.0116	CbGeAlD
Trametinib—CYP2C8—testis—sarcoma	0.000779	0.00936	CbGeAlD
Trametinib—CYP2C8—liver—sarcoma	0.000737	0.00885	CbGeAlD
Trametinib—CYP3A4—liver—sarcoma	0.000499	0.006	CbGeAlD
Trametinib—Angiopathy—Etoposide—sarcoma	0.000468	0.00154	CcSEcCtD
Trametinib—Hypertension—Mitoxantrone—sarcoma	0.000466	0.00153	CcSEcCtD
Trametinib—Mediastinal disorder—Etoposide—sarcoma	0.000465	0.00153	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000465	0.00153	CcSEcCtD
Trametinib—Chills—Etoposide—sarcoma	0.000463	0.00152	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000461	0.00151	CcSEcCtD
Trametinib—Cardiac failure congestive—Epirubicin—sarcoma	0.000461	0.00151	CcSEcCtD
Trametinib—Arthralgia—Mitoxantrone—sarcoma	0.00046	0.00151	CcSEcCtD
Trametinib—Myalgia—Mitoxantrone—sarcoma	0.00046	0.00151	CcSEcCtD
Trametinib—Renal failure acute—Epirubicin—sarcoma	0.000453	0.00149	CcSEcCtD
Trametinib—Oedema—Vincristine—sarcoma	0.000452	0.00148	CcSEcCtD
Trametinib—Infection—Vincristine—sarcoma	0.000449	0.00148	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Doxorubicin—sarcoma	0.000445	0.00146	CcSEcCtD
Trametinib—Nervous system disorder—Vincristine—sarcoma	0.000444	0.00146	CcSEcCtD
Trametinib—Decreased appetite—Thiotepa—sarcoma	0.000444	0.00146	CcSEcCtD
Trametinib—Thrombocytopenia—Vincristine—sarcoma	0.000443	0.00145	CcSEcCtD
Trametinib—Oedema—Mitoxantrone—sarcoma	0.000441	0.00145	CcSEcCtD
Trametinib—Gastrointestinal disorder—Thiotepa—sarcoma	0.00044	0.00145	CcSEcCtD
Trametinib—Decreased appetite—Dactinomycin—sarcoma	0.00044	0.00144	CcSEcCtD
Trametinib—Fatigue—Thiotepa—sarcoma	0.00044	0.00144	CcSEcCtD
Trametinib—Dysgeusia—Etoposide—sarcoma	0.00044	0.00144	CcSEcCtD
Trametinib—Infection—Mitoxantrone—sarcoma	0.000438	0.00144	CcSEcCtD
Trametinib—Hyperhidrosis—Vincristine—sarcoma	0.000437	0.00144	CcSEcCtD
Trametinib—Fatigue—Dactinomycin—sarcoma	0.000437	0.00143	CcSEcCtD
Trametinib—Constipation—Thiotepa—sarcoma	0.000436	0.00143	CcSEcCtD
Trametinib—Back pain—Etoposide—sarcoma	0.000434	0.00143	CcSEcCtD
Trametinib—Muscle spasms—Etoposide—sarcoma	0.000432	0.00142	CcSEcCtD
Trametinib—Thrombocytopenia—Mitoxantrone—sarcoma	0.000431	0.00142	CcSEcCtD
Trametinib—Skin disorder—Mitoxantrone—sarcoma	0.000428	0.0014	CcSEcCtD
Trametinib—Cardiac failure congestive—Doxorubicin—sarcoma	0.000426	0.0014	CcSEcCtD
Trametinib—Hyperhidrosis—Mitoxantrone—sarcoma	0.000426	0.0014	CcSEcCtD
Trametinib—Hyponatraemia—Epirubicin—sarcoma	0.00042	0.00138	CcSEcCtD
Trametinib—Renal failure acute—Doxorubicin—sarcoma	0.000419	0.00137	CcSEcCtD
Trametinib—Pain in extremity—Epirubicin—sarcoma	0.000418	0.00137	CcSEcCtD
Trametinib—Gastrointestinal pain—Thiotepa—sarcoma	0.000417	0.00137	CcSEcCtD
Trametinib—Anaemia—Etoposide—sarcoma	0.000415	0.00136	CcSEcCtD
Trametinib—Gastrointestinal pain—Dactinomycin—sarcoma	0.000414	0.00136	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Vincristine—sarcoma	0.000412	0.00135	CcSEcCtD
Trametinib—Insomnia—Vincristine—sarcoma	0.000409	0.00134	CcSEcCtD
Trametinib—Body temperature increased—Thiotepa—sarcoma	0.000403	0.00132	CcSEcCtD
Trametinib—Abdominal pain—Thiotepa—sarcoma	0.000403	0.00132	CcSEcCtD
Trametinib—Leukopenia—Etoposide—sarcoma	0.000402	0.00132	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000401	0.00132	CcSEcCtD
Trametinib—Abdominal pain—Dactinomycin—sarcoma	0.0004	0.00131	CcSEcCtD
Trametinib—Body temperature increased—Dactinomycin—sarcoma	0.0004	0.00131	CcSEcCtD
Trametinib—Decreased appetite—Vincristine—sarcoma	0.000393	0.00129	CcSEcCtD
Trametinib—Cough—Etoposide—sarcoma	0.000392	0.00129	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—sarcoma	0.000392	0.00129	CcSEcCtD
Trametinib—Gastrointestinal disorder—Vincristine—sarcoma	0.000391	0.00128	CcSEcCtD
Trametinib—Fatigue—Vincristine—sarcoma	0.00039	0.00128	CcSEcCtD
Trametinib—Dehydration—Epirubicin—sarcoma	0.000389	0.00128	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—sarcoma	0.000388	0.00127	CcSEcCtD
Trametinib—Hypertension—Etoposide—sarcoma	0.000388	0.00127	CcSEcCtD
Trametinib—Constipation—Vincristine—sarcoma	0.000387	0.00127	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—sarcoma	0.000387	0.00127	CcSEcCtD
Trametinib—Dry skin—Epirubicin—sarcoma	0.000383	0.00126	CcSEcCtD
Trametinib—Decreased appetite—Mitoxantrone—sarcoma	0.000383	0.00126	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—sarcoma	0.000382	0.00125	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—sarcoma	0.00038	0.00125	CcSEcCtD
Trametinib—Fatigue—Mitoxantrone—sarcoma	0.00038	0.00125	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00038	0.00125	CcSEcCtD
Trametinib—Constipation—Mitoxantrone—sarcoma	0.000377	0.00124	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000376	0.00124	CcSEcCtD
Trametinib—Gastrointestinal pain—Vincristine—sarcoma	0.00037	0.00121	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000369	0.00121	CcSEcCtD
Trametinib—Asthenia—Thiotepa—sarcoma	0.000366	0.0012	CcSEcCtD
Trametinib—Infection—Etoposide—sarcoma	0.000364	0.00119	CcSEcCtD
Trametinib—Asthenia—Dactinomycin—sarcoma	0.000363	0.00119	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—sarcoma	0.000362	0.00119	CcSEcCtD
Trametinib—Pruritus—Thiotepa—sarcoma	0.000361	0.00118	CcSEcCtD
Trametinib—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00036	0.00118	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—sarcoma	0.00036	0.00118	CcSEcCtD
Trametinib—Thrombocytopenia—Etoposide—sarcoma	0.000359	0.00118	CcSEcCtD
Trametinib—Abdominal pain—Vincristine—sarcoma	0.000358	0.00117	CcSEcCtD
Trametinib—Body temperature increased—Vincristine—sarcoma	0.000358	0.00117	CcSEcCtD
Trametinib—Skin disorder—Etoposide—sarcoma	0.000356	0.00117	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—sarcoma	0.000354	0.00116	CcSEcCtD
Trametinib—Hyperhidrosis—Etoposide—sarcoma	0.000354	0.00116	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—sarcoma	0.000354	0.00116	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—sarcoma	0.000353	0.00116	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—sarcoma	0.000352	0.00116	CcSEcCtD
Trametinib—Diarrhoea—Thiotepa—sarcoma	0.000349	0.00115	CcSEcCtD
Trametinib—Abdominal pain—Mitoxantrone—sarcoma	0.000348	0.00114	CcSEcCtD
Trametinib—Body temperature increased—Mitoxantrone—sarcoma	0.000348	0.00114	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000348	0.00114	CcSEcCtD
Trametinib—Diarrhoea—Dactinomycin—sarcoma	0.000346	0.00114	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000341	0.00112	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—sarcoma	0.000338	0.00111	CcSEcCtD
Trametinib—Dizziness—Thiotepa—sarcoma	0.000337	0.00111	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—sarcoma	0.000328	0.00108	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—sarcoma	0.000326	0.00107	CcSEcCtD
Trametinib—Asthenia—Vincristine—sarcoma	0.000325	0.00107	CcSEcCtD
Trametinib—Vomiting—Thiotepa—sarcoma	0.000324	0.00106	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—sarcoma	0.000322	0.00106	CcSEcCtD
Trametinib—Infestation—Epirubicin—sarcoma	0.000322	0.00106	CcSEcCtD
Trametinib—Vomiting—Dactinomycin—sarcoma	0.000322	0.00106	CcSEcCtD
Trametinib—Rash—Thiotepa—sarcoma	0.000322	0.00106	CcSEcCtD
Trametinib—Dermatitis—Thiotepa—sarcoma	0.000321	0.00105	CcSEcCtD
Trametinib—Headache—Thiotepa—sarcoma	0.00032	0.00105	CcSEcCtD
Trametinib—Rash—Dactinomycin—sarcoma	0.000319	0.00105	CcSEcCtD
Trametinib—Decreased appetite—Etoposide—sarcoma	0.000319	0.00105	CcSEcCtD
Trametinib—Renal failure—Epirubicin—sarcoma	0.000317	0.00104	CcSEcCtD
Trametinib—Gastrointestinal disorder—Etoposide—sarcoma	0.000316	0.00104	CcSEcCtD
Trametinib—Asthenia—Mitoxantrone—sarcoma	0.000316	0.00104	CcSEcCtD
Trametinib—Fatigue—Etoposide—sarcoma	0.000316	0.00104	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—sarcoma	0.000314	0.00103	CcSEcCtD
Trametinib—Constipation—Etoposide—sarcoma	0.000313	0.00103	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—sarcoma	0.000313	0.00103	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—sarcoma	0.000313	0.00103	CcSEcCtD
Trametinib—Diarrhoea—Vincristine—sarcoma	0.00031	0.00102	CcSEcCtD
Trametinib—Haematuria—Epirubicin—sarcoma	0.000307	0.00101	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—sarcoma	0.000304	0.000997	CcSEcCtD
Trametinib—Nausea—Thiotepa—sarcoma	0.000303	0.000995	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—sarcoma	0.000302	0.00099	CcSEcCtD
Trametinib—Diarrhoea—Mitoxantrone—sarcoma	0.000301	0.000989	CcSEcCtD
Trametinib—Nausea—Dactinomycin—sarcoma	0.000301	0.000987	CcSEcCtD
Trametinib—Gastrointestinal pain—Etoposide—sarcoma	0.0003	0.000984	CcSEcCtD
Trametinib—Dizziness—Vincristine—sarcoma	0.000299	0.000982	CcSEcCtD
Trametinib—Infestation—Doxorubicin—sarcoma	0.000298	0.000978	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—sarcoma	0.000298	0.000978	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—sarcoma	0.000294	0.000966	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—sarcoma	0.000293	0.000962	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—sarcoma	0.000291	0.000954	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—sarcoma	0.000291	0.000953	CcSEcCtD
Trametinib—Abdominal pain—Etoposide—sarcoma	0.00029	0.000951	CcSEcCtD
Trametinib—Body temperature increased—Etoposide—sarcoma	0.00029	0.000951	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—sarcoma	0.00029	0.000951	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—sarcoma	0.000289	0.000949	CcSEcCtD
Trametinib—Vomiting—Vincristine—sarcoma	0.000288	0.000944	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—sarcoma	0.000286	0.000937	CcSEcCtD
Trametinib—Rash—Vincristine—sarcoma	0.000285	0.000936	CcSEcCtD
Trametinib—Dermatitis—Vincristine—sarcoma	0.000285	0.000935	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—sarcoma	0.000285	0.000935	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—sarcoma	0.000284	0.000933	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—sarcoma	0.000284	0.000933	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—sarcoma	0.000283	0.00093	CcSEcCtD
Trametinib—Headache—Vincristine—sarcoma	0.000283	0.00093	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—sarcoma	0.000281	0.000923	CcSEcCtD
Trametinib—Vomiting—Mitoxantrone—sarcoma	0.00028	0.000919	CcSEcCtD
Trametinib—Rash—Mitoxantrone—sarcoma	0.000278	0.000912	CcSEcCtD
Trametinib—Dermatitis—Mitoxantrone—sarcoma	0.000278	0.000911	CcSEcCtD
Trametinib—Headache—Mitoxantrone—sarcoma	0.000276	0.000906	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—sarcoma	0.000272	0.000894	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—sarcoma	0.00027	0.000887	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—sarcoma	0.000269	0.000883	CcSEcCtD
Trametinib—Nausea—Vincristine—sarcoma	0.000269	0.000882	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—sarcoma	0.000268	0.000881	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—sarcoma	0.000268	0.000878	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—sarcoma	0.000264	0.000867	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—sarcoma	0.000264	0.000865	CcSEcCtD
Trametinib—Asthenia—Etoposide—sarcoma	0.000263	0.000863	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—sarcoma	0.000263	0.000863	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—sarcoma	0.000262	0.000861	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—sarcoma	0.000262	0.000861	CcSEcCtD
Trametinib—Nausea—Mitoxantrone—sarcoma	0.000262	0.000859	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—sarcoma	0.000261	0.000855	CcSEcCtD
Trametinib—Chills—Epirubicin—sarcoma	0.000259	0.000852	CcSEcCtD
Trametinib—Pruritus—Etoposide—sarcoma	0.000259	0.000851	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—sarcoma	0.000258	0.000848	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—sarcoma	0.000253	0.000831	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—sarcoma	0.000252	0.000826	CcSEcCtD
Trametinib—Erythema—Epirubicin—sarcoma	0.000252	0.000826	CcSEcCtD
Trametinib—Diarrhoea—Etoposide—sarcoma	0.000251	0.000823	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—sarcoma	0.00025	0.000821	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—sarcoma	0.000248	0.000815	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—sarcoma	0.000246	0.000809	CcSEcCtD
Trametinib—Back pain—Epirubicin—sarcoma	0.000243	0.000799	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—sarcoma	0.000243	0.000797	CcSEcCtD
Trametinib—Dizziness—Etoposide—sarcoma	0.000242	0.000795	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—sarcoma	0.000242	0.000794	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—sarcoma	0.000241	0.000791	CcSEcCtD
Trametinib—Chills—Doxorubicin—sarcoma	0.00024	0.000788	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—sarcoma	0.000239	0.000784	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—sarcoma	0.000237	0.000779	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—sarcoma	0.000234	0.000769	CcSEcCtD
Trametinib—Vomiting—Etoposide—sarcoma	0.000233	0.000765	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—sarcoma	0.000233	0.000764	CcSEcCtD
Trametinib—Erythema—Doxorubicin—sarcoma	0.000233	0.000764	CcSEcCtD
Trametinib—Anaemia—Epirubicin—sarcoma	0.000233	0.000764	CcSEcCtD
Trametinib—Rash—Etoposide—sarcoma	0.000231	0.000758	CcSEcCtD
Trametinib—Dermatitis—Etoposide—sarcoma	0.000231	0.000758	CcSEcCtD
Trametinib—Headache—Etoposide—sarcoma	0.00023	0.000754	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—sarcoma	0.000228	0.000749	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—sarcoma	0.000225	0.000739	CcSEcCtD
Trametinib—Back pain—Doxorubicin—sarcoma	0.000225	0.000739	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—sarcoma	0.000224	0.000735	CcSEcCtD
Trametinib—Cough—Epirubicin—sarcoma	0.00022	0.000721	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—sarcoma	0.000219	0.00072	CcSEcCtD
Trametinib—Nausea—Etoposide—sarcoma	0.000218	0.000714	CcSEcCtD
Trametinib—Hypertension—Epirubicin—sarcoma	0.000217	0.000713	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—sarcoma	0.000215	0.000706	CcSEcCtD
Trametinib—Myalgia—Epirubicin—sarcoma	0.000214	0.000703	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—sarcoma	0.000214	0.000703	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000213	0.000698	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—sarcoma	0.00021	0.000688	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—sarcoma	0.000208	0.000684	CcSEcCtD
Trametinib—Oedema—Epirubicin—sarcoma	0.000205	0.000674	CcSEcCtD
Trametinib—Infection—Epirubicin—sarcoma	0.000204	0.00067	CcSEcCtD
Trametinib—Cough—Doxorubicin—sarcoma	0.000203	0.000667	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—sarcoma	0.000201	0.000661	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—sarcoma	0.000201	0.00066	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—sarcoma	0.000201	0.00066	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—sarcoma	0.0002	0.000655	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—sarcoma	0.000199	0.000652	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—sarcoma	0.000198	0.000651	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—sarcoma	0.000198	0.000651	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000197	0.000646	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—sarcoma	0.000194	0.000636	CcSEcCtD
Trametinib—Oedema—Doxorubicin—sarcoma	0.00019	0.000624	CcSEcCtD
Trametinib—Infection—Doxorubicin—sarcoma	0.000189	0.00062	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000187	0.000614	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—sarcoma	0.000186	0.000612	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—sarcoma	0.000186	0.000611	CcSEcCtD
Trametinib—Insomnia—Epirubicin—sarcoma	0.000186	0.00061	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—sarcoma	0.000185	0.000606	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—sarcoma	0.000184	0.000603	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—sarcoma	0.000179	0.000586	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—sarcoma	0.000177	0.000582	CcSEcCtD
Trametinib—Fatigue—Epirubicin—sarcoma	0.000177	0.000581	CcSEcCtD
Trametinib—Constipation—Epirubicin—sarcoma	0.000176	0.000577	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000173	0.000568	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—sarcoma	0.000172	0.000564	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—sarcoma	0.000168	0.000551	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—sarcoma	0.000165	0.000542	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000164	0.000539	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—sarcoma	0.000164	0.000538	CcSEcCtD
Trametinib—Constipation—Doxorubicin—sarcoma	0.000163	0.000533	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—sarcoma	0.000162	0.000533	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—sarcoma	0.000162	0.000533	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—sarcoma	0.000155	0.00051	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—sarcoma	0.00015	0.000493	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—sarcoma	0.00015	0.000493	CcSEcCtD
Trametinib—Asthenia—Epirubicin—sarcoma	0.000147	0.000484	CcSEcCtD
Trametinib—Pruritus—Epirubicin—sarcoma	0.000145	0.000477	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—sarcoma	0.000141	0.000461	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—sarcoma	0.000136	0.000448	CcSEcCtD
Trametinib—Dizziness—Epirubicin—sarcoma	0.000136	0.000446	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—sarcoma	0.000134	0.000441	CcSEcCtD
Trametinib—Vomiting—Epirubicin—sarcoma	0.000131	0.000429	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—sarcoma	0.00013	0.000427	CcSEcCtD
Trametinib—Rash—Epirubicin—sarcoma	0.00013	0.000425	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—sarcoma	0.000129	0.000425	CcSEcCtD
Trametinib—Headache—Epirubicin—sarcoma	0.000129	0.000422	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—sarcoma	0.000126	0.000413	CcSEcCtD
Trametinib—Nausea—Epirubicin—sarcoma	0.000122	0.0004	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—sarcoma	0.000121	0.000397	CcSEcCtD
Trametinib—Rash—Doxorubicin—sarcoma	0.00012	0.000393	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—sarcoma	0.00012	0.000393	CcSEcCtD
Trametinib—Headache—Doxorubicin—sarcoma	0.000119	0.000391	CcSEcCtD
Trametinib—Nausea—Doxorubicin—sarcoma	0.000113	0.000371	CcSEcCtD
Trametinib—MAP2K2—Insulin Signaling—HRAS—sarcoma	9.09e-05	0.000223	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—KRAS—sarcoma	9.07e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K2—Downstream signal transduction—HRAS—sarcoma	9.05e-05	0.000222	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—KRAS—sarcoma	9.03e-05	0.000221	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signaling of activated FGFR—HRAS—sarcoma	9.01e-05	0.000221	CbGpPWpGaD
Trametinib—MAP2K2—EGF/EGFR Signaling Pathway—HRAS—sarcoma	9e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR—HRAS—sarcoma	9e-05	0.00022	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by ERBB2—HRAS—sarcoma	8.96e-05	0.000219	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	8.94e-05	0.000219	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 signaling—HRAS—sarcoma	8.92e-05	0.000218	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB4—HRAS—sarcoma	8.87e-05	0.000217	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—IL2—sarcoma	8.85e-05	0.000217	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ENO2—sarcoma	8.84e-05	0.000216	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	8.74e-05	0.000214	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	8.69e-05	0.000213	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KDR—sarcoma	8.67e-05	0.000212	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	8.66e-05	0.000212	CbGpPWpGaD
Trametinib—MAP2K1—MAPK Signaling Pathway—TP53—sarcoma	8.56e-05	0.00021	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCR4—sarcoma	8.54e-05	0.000209	CbGpPWpGaD
Trametinib—MAP2K1—Insulin Signaling—HRAS—sarcoma	8.51e-05	0.000208	CbGpPWpGaD
Trametinib—MAP2K1—Downstream signal transduction—HRAS—sarcoma	8.47e-05	0.000207	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	8.45e-05	0.000207	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR—HRAS—sarcoma	8.42e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K1—EGF/EGFR Signaling Pathway—HRAS—sarcoma	8.42e-05	0.000206	CbGpPWpGaD
Trametinib—MAP2K2—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	8.39e-05	0.000205	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by FGFR in disease—HRAS—sarcoma	8.39e-05	0.000205	CbGpPWpGaD
Trametinib—MAP2K2—DAP12 interactions—HRAS—sarcoma	8.39e-05	0.000205	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by ERBB2—HRAS—sarcoma	8.38e-05	0.000205	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	8.37e-05	0.000205	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 signaling—HRAS—sarcoma	8.34e-05	0.000204	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR—HRAS—sarcoma	8.31e-05	0.000204	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTPRC—sarcoma	8.3e-05	0.000203	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ENO2—sarcoma	8.27e-05	0.000203	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by EGFR in Cancer—HRAS—sarcoma	8.24e-05	0.000202	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by PDGF—HRAS—sarcoma	8.2e-05	0.000201	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	8.18e-05	0.0002	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CREB1—sarcoma	8.13e-05	0.000199	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PLCG1—sarcoma	8.12e-05	0.000199	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—SRC—sarcoma	8.12e-05	0.000199	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCR4—sarcoma	7.99e-05	0.000196	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—NRAS—sarcoma	7.94e-05	0.000195	CbGpPWpGaD
Trametinib—MAP2K2—Focal Adhesion—HRAS—sarcoma	7.93e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TLE1—sarcoma	7.92e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	7.9e-05	0.000194	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by FGFR in disease—HRAS—sarcoma	7.85e-05	0.000192	CbGpPWpGaD
Trametinib—MAP2K1—DAP12 interactions—HRAS—sarcoma	7.85e-05	0.000192	CbGpPWpGaD
Trametinib—MAP2K1—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	7.85e-05	0.000192	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—NRAS—sarcoma	7.81e-05	0.000191	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR—HRAS—sarcoma	7.78e-05	0.00019	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTPRC—sarcoma	7.77e-05	0.00019	CbGpPWpGaD
Trametinib—MAP2K1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	7.72e-05	0.000189	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ATF1—sarcoma	7.72e-05	0.000189	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by EGFR in Cancer—HRAS—sarcoma	7.71e-05	0.000189	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by PDGF—HRAS—sarcoma	7.68e-05	0.000188	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CREB1—sarcoma	7.61e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PLCG1—sarcoma	7.6e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—SRC—sarcoma	7.6e-05	0.000186	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—MMP2—sarcoma	7.57e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KIT—sarcoma	7.54e-05	0.000185	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PLCG1—sarcoma	7.5e-05	0.000184	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—NRAS—sarcoma	7.43e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	7.43e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Focal Adhesion—HRAS—sarcoma	7.42e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TLE1—sarcoma	7.41e-05	0.000182	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—SRC—sarcoma	7.35e-05	0.00018	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—NRAS—sarcoma	7.31e-05	0.000179	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ATF1—sarcoma	7.22e-05	0.000177	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CXCR4—sarcoma	7.21e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	7.18e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CREB1—sarcoma	7.18e-05	0.000176	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—VEGFA—sarcoma	7.16e-05	0.000175	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—EGFR—sarcoma	7.12e-05	0.000174	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—MMP2—sarcoma	7.08e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—NRAS—sarcoma	7.07e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KIT—sarcoma	7.06e-05	0.000173	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PLCG1—sarcoma	7.02e-05	0.000172	CbGpPWpGaD
Trametinib—MAP2K1—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	6.95e-05	0.00017	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—SRC—sarcoma	6.87e-05	0.000168	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—KRAS—sarcoma	6.84e-05	0.000167	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CXCR4—sarcoma	6.74e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—KRAS—sarcoma	6.72e-05	0.000165	CbGpPWpGaD
Trametinib—MAP2K1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	6.72e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CREB1—sarcoma	6.72e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—VEGFA—sarcoma	6.7e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFC—sarcoma	6.68e-05	0.000164	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—EGFR—sarcoma	6.66e-05	0.000163	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—NRAS—sarcoma	6.61e-05	0.000162	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—EGFR—sarcoma	6.44e-05	0.000158	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—KRAS—sarcoma	6.4e-05	0.000157	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—KRAS—sarcoma	6.29e-05	0.000154	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFC—sarcoma	6.25e-05	0.000153	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—KRAS—sarcoma	6.08e-05	0.000149	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—EGFR—sarcoma	6.03e-05	0.000148	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—MDM2—sarcoma	5.94e-05	0.000145	CbGpPWpGaD
Trametinib—MAP2K2—Cytokine Signaling in Immune system—HRAS—sarcoma	5.81e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—CTNNB1—sarcoma	5.8e-05	0.000142	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FOXO1—sarcoma	5.77e-05	0.000141	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PDGFRB—sarcoma	5.75e-05	0.000141	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by NGF—HRAS—sarcoma	5.71e-05	0.00014	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—KRAS—sarcoma	5.69e-05	0.000139	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PDGFRA—sarcoma	5.67e-05	0.000139	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—MDM2—sarcoma	5.56e-05	0.000136	CbGpPWpGaD
Trametinib—MAP2K1—Cytokine Signaling in Immune system—HRAS—sarcoma	5.44e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—CTNNB1—sarcoma	5.43e-05	0.000133	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FOXO1—sarcoma	5.39e-05	0.000132	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PDGFRB—sarcoma	5.38e-05	0.000132	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—HRAS—sarcoma	5.35e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FLT1—sarcoma	5.34e-05	0.000131	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FOXO1—sarcoma	5.32e-05	0.00013	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PDGFRB—sarcoma	5.31e-05	0.00013	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PDGFRA—sarcoma	5.3e-05	0.00013	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PLCG1—sarcoma	5.25e-05	0.000129	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—SRC—sarcoma	5.24e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PDGFRA—sarcoma	5.23e-05	0.000128	CbGpPWpGaD
Trametinib—MAP2K2—Axon guidance—HRAS—sarcoma	5.17e-05	0.000127	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—JUN—sarcoma	5.16e-05	0.000126	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—CTNNB1—sarcoma	5.12e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—VEGFA—sarcoma	5.11e-05	0.000125	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCR4—sarcoma	5.05e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NRAS—sarcoma	5.04e-05	0.000124	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FLT1—sarcoma	5e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ATF1—sarcoma	4.99e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FOXO1—sarcoma	4.98e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PDGFRB—sarcoma	4.97e-05	0.000122	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PLCG1—sarcoma	4.91e-05	0.00012	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—SRC—sarcoma	4.91e-05	0.00012	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PDGFRA—sarcoma	4.89e-05	0.00012	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—HRAS—sarcoma	4.84e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—JUN—sarcoma	4.83e-05	0.000118	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CTNNB1—sarcoma	4.79e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—sarcoma	4.78e-05	0.000117	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCR4—sarcoma	4.72e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NRAS—sarcoma	4.72e-05	0.000116	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ATF1—sarcoma	4.67e-05	0.000114	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—SRC—sarcoma	4.63e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—sarcoma	4.6e-05	0.000113	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CREB1—sarcoma	4.58e-05	0.000112	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NRAS—sarcoma	4.46e-05	0.000109	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KIT—sarcoma	4.39e-05	0.000108	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—sarcoma	4.34e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—SRC—sarcoma	4.33e-05	0.000106	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—sarcoma	4.3e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CREB1—sarcoma	4.28e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CREB1—sarcoma	4.18e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NRAS—sarcoma	4.17e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KIT—sarcoma	4.11e-05	0.000101	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—sarcoma	4.06e-05	9.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—sarcoma	4.06e-05	9.94e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KIT—sarcoma	4.06e-05	9.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1R—sarcoma	3.92e-05	9.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CREB1—sarcoma	3.91e-05	9.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CREB1—sarcoma	3.86e-05	9.45e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—sarcoma	3.83e-05	9.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—sarcoma	3.8e-05	9.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KIT—sarcoma	3.79e-05	9.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FOXO1—sarcoma	3.73e-05	9.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PDGFRB—sarcoma	3.72e-05	9.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—sarcoma	3.69e-05	9.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1R—sarcoma	3.66e-05	8.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PDGFRA—sarcoma	3.66e-05	8.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CREB1—sarcoma	3.61e-05	8.84e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—sarcoma	3.59e-05	8.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FOXO1—sarcoma	3.49e-05	8.54e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ENO2—sarcoma	3.49e-05	8.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PDGFRB—sarcoma	3.48e-05	8.52e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HBA1—sarcoma	3.46e-05	8.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MDM2—sarcoma	3.46e-05	8.47e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—sarcoma	3.45e-05	8.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PDGFRA—sarcoma	3.43e-05	8.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2—sarcoma	3.38e-05	8.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—sarcoma	3.26e-05	7.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MDM2—sarcoma	3.24e-05	7.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MDM2—sarcoma	3.19e-05	7.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—sarcoma	3.17e-05	7.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—sarcoma	3.09e-05	7.57e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KDR—sarcoma	3.08e-05	7.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—sarcoma	3.05e-05	7.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—JUN—sarcoma	3.01e-05	7.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MDM2—sarcoma	2.99e-05	7.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—sarcoma	2.98e-05	7.31e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PLCG1—sarcoma	2.96e-05	7.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—sarcoma	2.89e-05	7.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—sarcoma	2.88e-05	7.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—sarcoma	2.84e-05	6.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—sarcoma	2.84e-05	6.95e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—JUN—sarcoma	2.81e-05	6.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—sarcoma	2.79e-05	6.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—sarcoma	2.76e-05	6.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CREB1—sarcoma	2.7e-05	6.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SRC—sarcoma	2.7e-05	6.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—sarcoma	2.66e-05	6.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—sarcoma	2.66e-05	6.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—sarcoma	2.59e-05	6.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—sarcoma	2.59e-05	6.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—sarcoma	2.58e-05	6.31e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CREB1—sarcoma	2.53e-05	6.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SRC—sarcoma	2.52e-05	6.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SRC—sarcoma	2.49e-05	6.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—sarcoma	2.44e-05	5.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—sarcoma	2.43e-05	5.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—sarcoma	2.42e-05	5.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—sarcoma	2.4e-05	5.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—sarcoma	2.36e-05	5.79e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SRC—sarcoma	2.33e-05	5.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—sarcoma	2.29e-05	5.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—sarcoma	2.24e-05	5.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—sarcoma	2.24e-05	5.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—sarcoma	2.23e-05	5.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—sarcoma	2.23e-05	5.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—sarcoma	2.21e-05	5.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—sarcoma	2.18e-05	5.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—sarcoma	2.09e-05	5.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—sarcoma	2.09e-05	5.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—sarcoma	2.09e-05	5.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—sarcoma	2.08e-05	5.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—sarcoma	2.06e-05	5.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—sarcoma	2.04e-05	5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—sarcoma	2e-05	4.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—sarcoma	1.95e-05	4.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUN—sarcoma	1.94e-05	4.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—sarcoma	1.94e-05	4.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—sarcoma	1.93e-05	4.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—sarcoma	1.93e-05	4.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—sarcoma	1.9e-05	4.65e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO2—sarcoma	1.87e-05	4.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—sarcoma	1.87e-05	4.58e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HBA1—sarcoma	1.86e-05	4.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—sarcoma	1.82e-05	4.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUN—sarcoma	1.82e-05	4.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—sarcoma	1.81e-05	4.42e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—sarcoma	1.78e-05	4.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—sarcoma	1.75e-05	4.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SRC—sarcoma	1.74e-05	4.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—sarcoma	1.7e-05	4.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—sarcoma	1.68e-05	4.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—sarcoma	1.64e-05	4.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SRC—sarcoma	1.63e-05	4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—sarcoma	1.59e-05	3.89e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLCG1—sarcoma	1.59e-05	3.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—sarcoma	1.57e-05	3.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—sarcoma	1.56e-05	3.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—sarcoma	1.53e-05	3.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—sarcoma	1.46e-05	3.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—sarcoma	1.44e-05	3.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—sarcoma	1.43e-05	3.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—sarcoma	1.35e-05	3.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—sarcoma	1.28e-05	3.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—sarcoma	1.23e-05	3.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—sarcoma	1.2e-05	2.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—sarcoma	1.15e-05	2.81e-05	CbGpPWpGaD
